Oncorus, Inc.

DUBLIN--( BUSINESS WIRE )--The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including Executive and Consultant Guides. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. CAR-T Cells? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Already worth billions the global market is poised for dramatic growth. The impact on the health care industry is enormous. The report forecasts the market size out to 2027. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size. Make investment decisions and valuations with confidence using the latest data. This report explores the opportunity in this market and what companies are poised to benefit. Key Topics Covered: 1 Market Guides 1.1 Situation Analysis 1.2 Guide for Executives and Marketing Staff 1.3 Guide for Investment Analysts and Management Consultants 2 Introduction and Market Definition 2.1 What is Cancer Immunotherapy? 2.2 Immunotherapy - the looming cures 2.3 Market Definition 2.4 Methodology 2.5 U.S. Medical Market and Pharmaceutical Spending - Perspective 2.5.1 Global Expenditures for Medicines 3 Immunotherapy - Guide to Immune Technologies 3.1 The Immune System 3.1.1 Innate immune system 3.1.2 Adaptive immune system 3.1.3 Tumor immunology - the immune surveillance system 3.2 Immuno Oncology Technologies 3.2.1 Monoclonal Antibodies 3.2.2 Cancer vaccines 3.2.3 Cytokines 3.2.4 Cell Based Therapies 3.2.5 Inhibitors/Agonists 3.2.6 Antibody Drug Conjugates 3.2.7 Others 4 Industry Overview 4.1 Market Players - Roles & Impacts 4.1.1 Drug manufacturers - Larger/pharmaceutical 4.1.2 Drug manufacturers - Generic 4.1.3 Contract Research and Manufacturing 4.1.4 In Vitro Diagnostics Industry 4.1.5 Drug Marketing Companies 4.1.6 Biotechnology Companies 4.1.7 Regulatory Bodies 5 Market Trends 5.1 Factors Driving Growth 5.1.1 Outcome potential 5.1.2 Fast tracking 5.1.3 Funding 5.1.4 Technology Environment 5.1.5 Target Solutions 5.2 Factors Limiting Growth 5.2.1 Cost of Treatment 5.2.2 Clinical Trials Role 5.2.3 Combinations 5.2.4 Protocols 5.3 Therapeutic Technology Development 5.3.1 Combinations - Issues and Complexity 5.3.2 Preference for a drug 5.3.3 Problems of Immunity Engineering 5.3.4 The Role of Cost 5.3.5 The Disruption Dynamic 5.3.6 CAR-T Cell Therapy 5.3.7 The Next Five Years 6 Cancer Immunotherapy Recent Developments 6.1 Recent Developments - Importance and How to Use This Section 6.2 Continued Success with Immunotherapy in Melanoma 6.3 AC Immune Receives FDA Fast Track Designation 6.4 LTZ Announces Financing 6.5 Immunotherapy for Cancer Overview 6.6 Implantable device shrinks pancreatic tumors 6.7 mRNA Vaccine And Immunotherapy Reduce Melanoma Recurrence 6.8 Towards a Universal Cancer Immunotherapy 6.9 New Strategy May Improve T-Cell Therapy in Solid Tumors 6.10 Immunotherapy linked to increase in Medicare spending 6.11 Immunotherapy Effective with Ovarian Cancer 6.12 Cancer Immunotherapy Granted Fast Track 7 Profiles of Key Immunotherapy Companies AbbVie Achilles Therapeutics Acumen Pharmaceuticals Adagene Adaptimmune Therapeutics Adicet Bio ALX Oncology Holdings Ambrx Biopharma Amgen Apexigen Arcus Biosciences argenx AstraZeneca Atreca Avalo Therapeutics Avid Bioservices Bavarian Nordic BioAtla Biogen Inc. BioNTech Bolt Biotherapeutics Bristol-Myers Squibb Candel Therapeutics Caribou Biosciences Celldex Therapeutics Checkpoint Therapeutics Chinook Therapeutics Corvus Pharmaceuticals Cullinan Oncology Eli Lilly EOM Pharmaceuticals Evaxion Biotech Genenta Science Gilead Sciences Gracell Biotechnologies Greenwich LifeSciences Gritstone bio Harpoon Therapeutics ImmunityBio Immunocore Holdings Immunome IMV Inc Incyte Indaptus Therapeutics Instil Bio Iovance Biotherapeutics Johnson & Johnson Marker Therapeutics Medicenna Therapeutics Merck & Co. Merus Moderna Mustang Bio Nanobiotix Neoleukin Therapeutics Novartis Novavax Oncorus PDS Biotechnology Pfizer Regeneron Pharmaceuticals Roche Sanofi Sensei Biotherapeutics Senti Biosciences Surface Oncology Takeda Pharmaceutical TC Biopharm ThermoGenesis Holdings UroGen Pharma Werewolf Therapeutics Xilio Therapeutics Zymeworks 8 The Global Market for Immuno-Oncology Therapeutics 8.1 Global Market Overview by Country 8.2 Global Market by Therapy 8.3 Global Market by Cancer 8.4 Global Market by Customer 9 Global Immuno-Oncology Therapy Markets - By Therapy 9.1 MAB 9.2 Cytokine 9.3 Vaccine 9.4 Cell Based 9.5 Inhibitor/Agonist 9.6 Other IO Therapy 10 Global Immuno-Oncology Therapeutic Markets - By Cancer 10.1 Breast 10.2 ColoRectal 10.3 Cervical 10.4 Lung 10.5 Precancer 10.6 Prostate 10.7 Melanoma 10.8 Blood 10.9 Other Cancer 11 Global Immuno-Oncology Therapeutic Markets - By Customer 11.1 Pharma 11.2 Clinic 11.3 Other Customer For more information about this report visit https://www.researchandmarkets.com/r/8355qg About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Pheon Therapeutics has pulled in another $120 million to fund its differentiated antibody-drug conjugate (ADC) pipeline, with its lead asset expected to enter the clinic later this year. CEO Cyrus Mozayeni called the Series B “a critical step” for the company, which emerged from stealth in 2022.At that time, Pheon was led by Bertrand Damour, with Mozayeni being appointed last year to drive the company’s growth. Prior to Pheon, Mozayeni co-founded Vedere Bio, serving as chief executive from inception through to its $280-million sale to Novartis. Mozayeni also founded CODA Biotherapeutics and Oncorus, as well as working in business development at bluebird bio.According to Pheon, the latest financing – led by TCGX, with participation from new investors BVF Partners, Lightspeed and Perceptive Advisors – will be used to advance its pipeline through clinical proof-of-concept. The company’s first three assets are aimed at an undisclosed novel target, which is highly overexpressed in a wide range of solid tumours.The first candidate, dubbed PHN-010, utilises a DAR8 Topoisomerase-1 inhibitor linker-payload, while the other two comprise different linker-payload technologies in an effort “to mine the broad potential” of the target.

CAMBRIDGE, Mass., Sept. 6, 2023 /PRNewswire/ -- Convergent Therapeutics Inc., a clinical-stage biotechnology company, today announced the expansion of its leadership team with the appointments of Neil Bander, MD, as Chief Scientific Officer, Eric M. Sullivan as Chief Financial Officer, and Dimitris Voliotis, MD, as Senior Vice President of Clinical Development. These appointments follow the company's recent closing of a $90 million Series A financing round to develop radiopharmaceuticals to treat cancer. "Dr. Bander, Mr. Sullivan, and Dr. Voliotis bring decades of experience to Convergent that will support the rapid growth of the company and the development of our portfolio," said Dr. Philip Kantoff, CEO of Convergent. "With our strong financial backing, we are poised to accelerate the clinical development of our lead asset CONV01-a to transform the lives of patients suffering with prostate cancer." Dr. Bander, who moves from a role as Founder and Chief Scientific Advisor was instrumental in the development of the first antibody to target the extracellular domain of prostate-specific membrane antigen (PSMA) on prostate cancer cells. Over the past 25 years, Dr. Bander pioneered the development of PSMA-targeted imaging agents and therapeutics, transforming the prostate cancer landscape. As Bernard & Josephine Chaus Professor of Urologic Oncology at Weill Cornell Medicine, Dr. Bander authored approximately 200 peer-reviewed publications and is an inventor on approximately 150 U.S. and foreign-issued and pending patents. He has also served on and chaired multiple study sections, grant review panels, and industry scientific advisory boards. He has received several honors, including the FC Valentine Fellowship from the NY Academy of Medicine and the Society of Surgical Oncology James Ewing Research Award, as well as awards from the German and Japanese Urology Societies, the Prostate Cancer Foundation, and the Clark Medal for Surgical Innovation from the Royal College of Surgeons (London). As the newly appointed CFO, Mr. Sullivan joins Convergent after serving as the CFO of TCR2 Therapeutics, which was recently acquired by Adaptimmune for approximately $110 million. He has extensive financial experience in the biotechnology field, having led finance functions at high-growth public companies, including Bluebird Bio and Merrimack Pharmaceuticals, and at privately held companies, including Oncorus, Gemini and Triplet. Dr. Voliotis is joining Convergent from Zentalis Pharmaceuticals, where he was Senior Vice President & Head of Global Development. At Zentalis, he was responsible for leading four INDs, associated clinical studies in solid tumor oncology and hematology-oncology indications, as well as the coordination of multiple clinical pipeline projects. Prior to joining Zentalis, he had 18 years of successful pharmaceutical/biotech industry experience in development leadership positions at Eisai and Bayer Healthcare. Dr. Voliotis has been involved in the development of over 50 compounds, including small molecule targeted therapeutics, monoclonal antibodies, immunoconjugates and the radiopharmaceutical Xofigo, which was approved for use in metastatic prostate cancer. About Convergent Therapeutics, Inc. Convergent Therapeutics Inc. is a clinical-stage biotechnology company focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology was developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine, and licensed to Convergent by Cornell University. CONV01-α, a monoclonal antibody conjugated to actinium-225 (Ac-225), a radioactive alpha particle emitter, was specifically designed to bind to the prostate-specific membrane antigen (PSMA). A key functional feature of CONV01-α is that once bound to PSMA, it becomes internalized, delivering its powerful radioactive payload directly into prostate cancer cells while minimizing damage to surrounding healthy tissue. CONV01-α has the potential to be the first Ac-225 radioantibody approved for use in prostate cancer treatment. For more information, please visit and follow us on Twitter and LinkedIn. Convergent Media Contact Olipriya Das, Ph.D. Russo Partners, LLC (409) 365-3641 olipriya.das@russopartnersllc.com